Prostate Cancer News and Latest Research
- Specific molecular alterations explain discordance between genomic and clinical risk in localized prostate cancer Retrospective · Clin Cancer Res · 2026-11-18
Across 287,145 patients, TP53, PTEN, AR activity and RB1 status were linked to discordance between Decipher Genomic Classifier and NCCN risk groups; adverse molecular features added prognostic information for distant metastasis in high-risk patients.
Why it matters: Suggests molecular feature profiling could refine risk stratification beyond genomic classifier scores alone in high-risk disease.
- Opioid-free anesthesia shows no significant benefit over opioid-based technique in prostatectomy RCT · World J Urol · 2026-11-18
In a 57-patient randomized trial, opioid-free anesthesia did not significantly reduce 24-hour postoperative oxycodone consumption or pain scores compared with remifentanil-based anesthesia during laparoscopic radical prostatectomy.
Why it matters: Suggests opioid-free protocols are not clearly superior for postoperative analgesia in this setting, though trial was underpowered for equivalence.
- Elevated neutrophil-lymphocyte ratio linked to worse survival on 177Lu-PSMA-617 therapy Retrospective · Prostate Cancer Prostatic Dis · 2026-11-16
In a two-institution retrospective analysis of 501 mCRPC patients treated with 177Lu-PSMA-617 after taxane therapy, a neutrophil-lymphocyte ratio above 3 at the first cycle was independently associated with worse survival, with persistently elevated NLR through cycle 2 linked to the poorest outcomes.
Why it matters: Raises the question of whether a simple blood ratio could help flag patients needing closer monitoring during PSMA radioligand therapy, but needs prospective validation.
- Systematic review underlying new ACS guideline summarizes benefits and harms of PSA screening Meta-analysis · Cancer · 2026-11-13
A systematic review of 29 publications, including 23 from six randomized trials (PLCO, CAP, ERSPC, Goteborg-1, Rotterdam Pilot 1, ProScreen) and four observational studies, found PSA screening was associated with reduced incidence of advanced/metastatic disease and, in some trials, reduced prostate cancer-specific mortality, though findings on mortality were inconsistent.
Why it matters: Provides the evidence base, drawn from a systematic review of RCTs and observational studies, behind the updated ACS PSA screening guideline, useful for shared decision-making conversations.
- Meta-analysis: active surveillance shows similar mortality to surgery, but watchful waiting worse Meta-analysis · Clin Genitourin Cancer · 2026-11-13
Across 12 studies (36,993 patients), active surveillance showed no significant difference in cancer-specific or all-cause mortality versus radical prostatectomy, though evidence was underpowered; watchful waiting was associated with significantly higher cancer-specific and all-cause mortality than surgery.
Why it matters: Suggests active surveillance and watchful waiting are not interchangeable, though the active surveillance comparison remains underpowered.
- PSMA total tumor volume outpredicts SUV and PSA for overall survival in large PET registry Retrospective · J Nucl Med · 2026-11-13
Among 13,893 prostate cancer patients in the PROMISE PET Registry split into development (n=9271) and validation (n=4622) cohorts, PSMA total tumor volume predicted overall survival in the validation cohort with a C-index of 0.78 (95% CI, 0.77-0.80), outperforming whole-body SUVmean (0.62; 95% CI, 0.61-0.64) and PSA at PET (0.71; 95% CI, 0.69-0.72), and performing similarly to PSMA total lesion uptake (0.78) and PSA times TTV (0.77).
Why it matters: A straightforward volumetric PSMA PET measurement may offer a more reliable way to stratify overall survival risk than SUV or PSA alone.
- FDA grants breakthrough therapy designation to 64Cu-SAR-bisPSMA PET agent FDA action · OncLive · 2026-11-12
FDA granted Breakthrough Therapy Designation to 64Cu-SAR-bisPSMA, a PSMA PET imaging agent, for detecting biochemically recurrent prostate cancer.
Why it matters: Designation may accelerate review of a new long-lived PSMA PET tracer option for recurrence imaging.
- NCCN adds ArteraAI post-prostatectomy test to guideline for biochemical recurrence risk News · Targeted Oncology · 2026-11-12
NCCN guidelines now include the ArteraAI test, an AI-based prognostic tool, for risk assessment after radical prostatectomy in the setting of biochemical recurrence.
Why it matters: Signals growing guideline incorporation of AI-based prognostic biomarkers into routine post-prostatectomy decision-making.
- ctDNA positivity before SBRT predicts rapid progression in oligoprogressive CRPC Retrospective · JAMA Netw Open · 2026-11-12
In this prespecified secondary analysis of the phase 2 TRAP trial, 19 of 77 evaluable patients (24.7%) were ctDNA-positive before SBRT; their 6-month progression-free survival was 21.1% versus 58.3% for ctDNA-negative patients, with median PFS of 3.0 versus 7.8 months (P = .003). Median overall survival was 27.2 months for ctDNA-positive patients and 33.6 months for ctDNA-negative patients.
Why it matters: Baseline ctDNA status may help identify oligoprogressive CRPC patients less likely to benefit from SBRT, supporting its potential use in selecting candidates for metastasis-directed therapy versus earlier systemic change.
- CT adds little over pelvic MRI for nodal staging in higher-risk prostate cancer, both poor vs pathology Retrospective · World J Urol · 2026-11-12
In 323 patients with unfavorable intermediate- or high-risk prostate cancer, MRI and CT showed only moderate agreement for nodal staging and both had low sensitivity (≤20%) versus surgical pathology; PSMA PET/CT performed better (AUC 0.86) in a subgroup with molecular imaging.
Why it matters: Raises the question of whether conventional CT adds meaningful nodal staging value when PSMA PET is available.
- PSMA-guided salvage surgery shows PSA decline but limited durable cancer control Study · Renal & Urology News · 2026-11-10
A study of PSMA PET-guided salvage lymph node dissection or metastasectomy reported PSA declines in many patients but limited long-term disease control.
Why it matters: Suggests PSMA-guided salvage surgery may offer short-term biochemical benefit without durable oncologic control in recurrent prostate cancer.
- Registered trial: phase 3 trial to test perioperative relugolix around radical prostatectomy Trial registered · ClinicalTrials.gov · 2026-11-10
A phase 3 trial will randomize about 268 men with high-risk localized or locally advanced prostate cancer to relugolix before and after radical prostatectomy versus surgery alone followed by relugolix, evaluating this LHRH antagonist in a perioperative role. Registered on ClinicalTrials.gov and not yet recruiting; estimated start 2027-01-31; planned enrollment 268.
- NICE recommends five AI tools for prostate cancer detection in England Intl regulatory · UKAuthority · 2026-11-10
NICE issued recommendations backing five AI-based software tools to assist detection of prostate cancer, intended for use within the English NHS.
Why it matters: Signals a regulatory pathway for AI-assisted prostate cancer detection that US-based urologists should track.
- Single-arm TULSA study reports 12-month outcomes for localized prostate cancer Phase 1-2 · BJU Int · 2026-11-10
In a single-center phase II study of lesion-targeted transurethral ultrasound ablation in 59 men, 70% were free of in-field grade group 2+ cancer and 52% were free of prostate-wide grade group 2+ cancer at 12 months; no grade 3+ complications occurred within 3 months.
Why it matters: Adds early single-arm safety and efficacy data for a focal ablation technique in localized prostate cancer, but about half had residual clinically significant disease elsewhere in the gland.
- Review catalogs 45 non-cancer factors that can raise or lower PSA levels Review · Prostate · 2026-11-10
A narrative review consolidates 45 benign physiologic, infectious, inflammatory, iatrogenic, hormonal, pharmacologic, and laboratory factors shown to elevate (30 factors) or reduce (15 factors) PSA, including infection, instrumentation, 5-alpha-reductase inhibitors, NSAIDs, statins, and assay variability exceeding 20% between labs.
Why it matters: Offers a practical reference for interpreting borderline PSA results and avoiding unnecessary biopsies driven by false-positive or false-negative PSA elevations or reductions.
- SEER-Medicare analysis finds lower urinary adverse events after robotic vs open prostatectomy Retrospective · Transl Androl Urol · 2026-11-08
In a SEER-Medicare cohort of 17,441 beneficiaries aged 66+, robot-assisted radical prostatectomy was associated with lower urinary adverse events than non-robotic approaches (7.7% vs 15.3%), driven mainly by bladder outlet and ureteral obstruction; incontinence rates did not differ, and the association was not detectable beyond 3 years.
Why it matters: Hypothesis generating only; claims-based SEER-Medicare data lack granular surgical and pathologic detail and cannot establish causality for approach selection.
- Patient-provider communication quality linked to treatment choice and prostate cancer mortality in cohort study Prospective · JCO Oncol Pract · 2026-11-07
In a population-based cohort of 2,258 Black and White men followed through 2020, higher communication content scores were associated with greater odds of definitive treatment, shorter time to surgery, and lower prostate cancer-specific mortality (sHR 0.78, 95% CI 0.61-0.99).
Why it matters: A long-term cohort study found that men who reported better communication content with their doctors were more likely to get definitive treatment and had lower prostate cancer-specific mortality risk, though this is an…
- Prior cancer history linked to higher germline mutation rates in prostate cancer registry Retrospective · Eur Urol Focus · 2026-11-06
Among 42,645 prostate cancer patients in a germline testing registry, mutation prevalence rose from 10% with no prior cancer to 18% with two or more prior cancers, with the strongest associations seen for prior ureteral, bladder, and colon cancer.
Why it matters: Raises the question of whether a history of additional cancers, rather than family history alone, is associated with germline testing yield in prostate cancer patients.
Urology clinical trials · Urology podcasts · Urology videos · Meetings · Daily edition archive
Loading today's edition…